Aclaris Therapeutics (ACRS) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 84.8% versus a gain of 11.8%. Aclaris Therapeutics is the larger company by market cap ($496.1 million vs $481.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | CTNM |
|---|---|---|
| Share price | $3.37 | $12.81 |
| Market cap | $496.06M | $481.74M |
| 1-day change | -0.88% | +0.59% |
| YTD return | +12.96% | +11.37% |
| 1-year return | +84.78% | +11.76% |
| 5-year return | -79.77% | — |
| EPS (TTM) | $-0.58 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $17.79 |
| 52-week low | $1.74 | $8.60 |
| Distance from 52-week high | -48.94% | -28.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +202.08% | +75.17% |
| Average volume | 2.48M | 502.82K |
| Shares outstanding | 147.20M | 32.96M |
| Employees | 69 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed CTNM by 73.0 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
ACRS vs CTNM FAQ
Which is bigger, Aclaris Therapeutics or Contineum Therapeutics?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $496.06M compared with $481.74M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, ACRS or CTNM?
ACRS returned +84.78% over the past 12 months, compared with +11.76% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.